Q3 2025 Earnings

Revenue

$9M+9.1% YoY

Gross Profit

$6M63.2% margin

Operating Income

-$5M-59.5% margin

Net Income

-$6M-66.5% margin

EPS (Diluted)

$-0.21

QoQ Revenue Growth

-3.8%

Operating Cash Flow

-$3M

Free Cash Flow

-$3M

Stock-Based Comp.

$2M

Total Assets

$60M

Total Liabilities

$44M

Stockholders' Equity

$16M

Cash & Equivalents

$38M

Metric	Current	Year Ago	Change
Revenue	$9M	$8M	+9.1%
Gross Profit	$6M	$5M	+15.5%
Operating Income	-$5M	-$5M	-2.0%
Net Income	-$6M	-$5M	-18.4%

Biologics And Drug Delivery

$4M57%

Biologics And Drug Delivery - Disposable Products

$1M17%

Capital Equipment And Software

$1M13%

Capital Equipment And Software - Systems and Software Products

$647,0008%

Capital Equipment And Software - Services

$390,0005%